The management of patients with advanced germ-cell tumors: Seminoma and nonseminoma Journal Article


Authors: Law, T. M.; Motzer, R. J.; Bajorin, D. F.; Bosl, G. J.
Article Title: The management of patients with advanced germ-cell tumors: Seminoma and nonseminoma
Abstract: Treatment strategies for germ cell tumors have evolved substantially during the last decade and are directed by pretreatment prognostic factors that include histology (seminoma versus nonseminoma), primary site of disease, serum concentrations of lactate dehydrogenase and human chorionic gonadotropin, and the number of metastatic sites of disease. Patients with a high likelihood of achieving a complete response to therapy (CR0.5) are considered ''good risk'' and receive three or four cycles of cisplatin-based chemotherapy. Patients with a low likelihood of achieving a complete response (CR0.5) are considered ''poor risk'' and should be considered for innovative treatment strategies with the intent of increasing the proportion of patients who are cured. One approach in patients with ''poor risk'' disease uses early treatment with high-dose chemotherapy and autologous bone marrow transplantation. In addition, effective salvage regimens are available for those patients who fail first-line therapy.
Keywords: salvage therapy; chemotherapy; combination chemotherapy; phase-ii trial; adjuvant; bone-marrow transplantation; primary site; high-dose carboplatin; unknown; disseminated testicular cancer; poorly differentiated carcinoma; marker half-life
Journal Title: Urologic Clinics of North America
Volume: 21
Issue: 4
ISSN: 0094-0143
Publisher: W.B. Saunders Co-Elsevier Inc.  
Date Published: 1994-11-01
Start Page: 773
End Page: 783
Language: English
ACCESSION: WOS:A1994PT31600022
PROVIDER: wos
PUBMED: 7974906
Notes: Source: Wos
Citation Impact
MSK Authors
  1. Dean Bajorin
    657 Bajorin
  2. Robert Motzer
    1243 Motzer
  3. George Bosl
    430 Bosl